BioProspect raises $1.2m
Tuesday, 24 January, 2006
Natural pesticide developer BioProspect (ASX:BPO) has raised AUD$1.2 million from its fully underwritten rights offer, where shareholders could subscribe for one new share, at a price of $0.02, and a free attaching option for every three shares held.
The Brisbane-based firm had planned to raise $1.4 million, and the shortfall will be placed by the company and its underwriter. BioProspect's shares were trading at $0.021 at the time of writing.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
